Search

Search Constraints

You searched for: Author/Creator Oji, Yusuke

Search Results

1. A Zbtb7a proto‐oncogene as a novel target for miR‐125a. Issue 12 (29th December 2015)

2. An Essential Role of the Avidity of T-Cell Receptor in Differentiation of Self-Antigen-reactive CD8+ T Cells. Issue 3 (April 2016)

3. Association of WT1 IgG antibody against WT1 peptide with prolonged survival in glioblastoma multiforme patients vaccinated with WT1 peptide. Issue 6 (31st May 2016)

4. Cellular and Humoral Immune Responses Induced by an HLA Class I–restricted Peptide Cancer Vaccine Targeting WT1 Are Associated With Favorable Clinical Outcomes in Advanced Ovarian Cancer. Issue 1 (8th January 2022)

5. Cellular and Humoral Immune Responses Induced by an HLA Class I–restricted Peptide Cancer Vaccine Targeting WT1 Are Associated With Favorable Clinical Outcomes in Advanced Ovarian Cancer. Issue 1 (January 2022)

6. Distinct difference in tumor-infiltrating immune cells between Wilms' tumor gene 1 peptide vaccine and anti-programmed cell death-1 antibody therapies. Issue 1 (29th June 2021)

7. Enhanced immune reaction resulting from co-vaccination of WT1 helper peptide assessed on PET-CT. Issue 39 (25th September 2020)

8. Feasibility of Cancer Immunotherapy with WT1 Peptide Vaccination for Solid and Hematological Malignancies in Children. Issue 2 (15th October 2015)

9. Immune adjuvant therapy using Bacillus Calmette–Guérin cell wall skeleton (BCG-CWS) in advanced malignancies: A phase 1 study of safety and immunogenicity assessments. Issue 33 (August 2019)

10. IMT-07 CLINICAL TRIAL OF A COCKTAIL WILMS' TUMOR 1 (WT1) VACCINATION USING TWO HLA CLASS I PEPTIDES AND ONE CLASS II PEPTIDE FOR RECURRENT MALIGNANT GLIOMAS. (16th December 2019)